BioCryst Pharmaceuticals Net Worth
BioCryst Pharmaceuticals Net Worth Breakdown | BCRX |
BioCryst Pharmaceuticals Net Worth Analysis
BioCryst Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including BioCryst Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of BioCryst Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform BioCryst Pharmaceuticals' net worth analysis. One common approach is to calculate BioCryst Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares BioCryst Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing BioCryst Pharmaceuticals' net worth. This approach calculates the present value of BioCryst Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of BioCryst Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate BioCryst Pharmaceuticals' net worth. This involves comparing BioCryst Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into BioCryst Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if BioCryst Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding BioCryst Pharmaceuticals' net worth research are outlined below:
| BioCryst Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 450.71 M. Net Loss for the year was (88.88 M) with profit before overhead, payroll, taxes, and interest of 264.79 M. | |
| BioCryst Pharmaceuticals currently holds about 417.48 M in cash with (52.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.24. | |
| Over 81.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Institutional investors control 75 percent of BioCryst Pharmaceuticals, Inc. and were rewarded last week after stock increased 4.9 |
BioCryst Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in BioCryst Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to BioCryst Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know BioCryst Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as BioCryst Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BioCryst Pharmaceuticals backward and forwards among themselves. BioCryst Pharmaceuticals' institutional investor refers to the entity that pools money to purchase BioCryst Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Caligan Partners Lp | 2024-12-31 | 3 M | Gw&k Investment Management, Llc | 2024-12-31 | 2.9 M | Rock Springs Capital Management Lp | 2024-12-31 | 2.7 M | Two Sigma Advisers, Llc | 2024-12-31 | 2.5 M | Rice Hall James & Associates, Llc | 2024-12-31 | 2.1 M | Northern Trust Corp | 2024-12-31 | 2 M | Eversept Partners, Llc | 2024-12-31 | 2 M | Charles Schwab Investment Management Inc | 2024-12-31 | 2 M | Stifel Financial Corp | 2024-12-31 | 1.8 M | Blackrock Inc | 2024-12-31 | 22.1 M | Vanguard Group Inc | 2024-12-31 | 21.9 M |
Follow BioCryst Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.61 B.Market Cap |
|
Project BioCryst Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.18) | (0.19) | |
| Return On Capital Employed | (0.01) | (0.01) | |
| Return On Assets | (0.18) | (0.19) | |
| Return On Equity | 0.19 | 0.20 |
When accessing BioCryst Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures BioCryst Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of BioCryst Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in BioCryst Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of BioCryst Pharmaceuticals. Check BioCryst Pharmaceuticals' Beneish M Score to see the likelihood of BioCryst Pharmaceuticals' management manipulating its earnings.
Evaluate BioCryst Pharmaceuticals' management efficiency
Return On Equity is likely to rise to 0.20 in 2025, whereas Return On Tangible Assets are likely to drop (0.19) in 2025. At this time, BioCryst Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 71.9 M in 2025, whereas Other Current Assets are likely to drop slightly above 9.8 M in 2025. BioCryst Pharmaceuticals' management efficiency ratios could be used to measure how well BioCryst Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (2.30) | (2.19) | |
| Tangible Book Value Per Share | (2.30) | (2.19) | |
| Enterprise Value Over EBITDA | 114.18 | 119.89 | |
| Price Book Value Ratio | (3.27) | (3.10) | |
| Enterprise Value Multiple | 114.18 | 119.89 | |
| Price Fair Value | (3.27) | (3.10) | |
| Enterprise Value | 112.6 M | 115.2 M |
The strategic initiatives led by BioCryst Pharmaceuticals' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 4.6477 | Revenue | Quarterly Revenue Growth 0.408 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioCryst Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioCryst Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BioCryst Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
BioCryst Pharmaceuticals Corporate Filings
8K | 11th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10K | 25th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
F4 | 23rd of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 7th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
BioCryst Pharmaceuticals Earnings per Share Projection vs Actual
BioCryst Pharmaceuticals Corporate Management
| Yarlagadda Babu | Sr. VP of Drug Discovery | Profile | |
| Alane Barnes | VP, General Counsel and Corporate Secretary | Profile | |
| Elliott Berger | VP Affairs | Profile | |
| William MBBS | Chief Officer | Profile | |
| Stephanie Angelini | Chief Officer | Profile | |
| Michael Jones | Executive Officer | Profile | |
| Clayton Fletcher | Chief Officer | Profile |
Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.